Every Form 4 that Phathom Pharmaceuticals, Inc. (PHAT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PHAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PHAT filings page.
Phathom Pharmaceuticals, Inc. (PHAT) reported that Principal Accounting Officer Robert Charles Breedlove surrendered shares on September 3, 2026 to cover taxes on equity compensation. He delivered 460 shares of common stock, valued at $9.05 per share, to satisfy the company’s tax withholding obligation on vested restricted stock units.
After this withholding event, he continued to hold 59,465 shares of Phathom common stock directly, plus an additional 8,191.78 shares held indirectly through a 401(k) plan. No transactions were reported as being made under a Rule 10b5-1 trading plan.
Phathom Pharmaceuticals, Inc. principal accounting officer Robert Charles Breedlove reported an F-code tax-withholding disposition of 1,555 shares of common stock on July 14, 2026, at $11.035 per share, surrendering shares underlying restricted stock units to the issuer to satisfy its tax withholding obligation. After this event, he holds 59,925.0000 shares directly and 6,945.4000 shares indirectly through a 401(k) plan.
Phathom Pharmaceuticals director Asit Parikh reported gifting company shares rather than trading them in the market. On May 22, 2026, he made two bona fide gift transfers totaling 56,000 shares of common stock. One 28,000-share gift came from indirect holdings "by Trust" and another 28,000-share gift came from his direct holdings.
Following these gifts, Parikh’s reported indirect holdings were 148,500 shares, and his direct holdings were 24,122 shares. A footnote explains that the transferred shares went for no consideration to a trust benefiting his spouse, for which he serves as trustee, highlighting that this filing reflects estate or family planning rather than open-market buying or selling.
Phathom Pharmaceuticals director Asit Parikh reported equity compensation and an option exercise that increased his share holdings. He exercised options to acquire 17,500 shares of common stock at $4.95 per share, and the corresponding right to buy 17,500 shares was surrendered back to the company.
Parikh also received a grant of 24,122 Restricted Stock Units under the Non-Employee Director Compensation Program. These RSUs vest in full on the earlier of the first anniversary of the May 19, 2026 grant date or the next annual stockholder meeting, subject to continued board service. After these transactions, he holds 52,122 shares directly and 120,500 shares indirectly through a trust.
Phathom Pharmaceuticals director James N. Topper received an equity grant in the form of restricted stock units. On May 19, 2026, he was awarded 24,122 RSUs at a price of $0.00 per share under the company’s Non-Employee Director Compensation Program. These RSUs vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, as long as he continues serving on the board. Each RSU converts into one share of common stock when it vests. After this grant, Topper directly holds 66,718 common shares, alongside additional indirect holdings through several Frazier Life Sciences and related entities, some of which he reports with limited pecuniary interest.
Phathom Pharmaceuticals director Mark Stenhouse received a grant of 24,122 Restricted Stock Units (RSUs) of common stock. The award was granted on May 19, 2026 under the company’s Non-Employee Director Compensation Program and carries no cash exercise price.
All 24,122 RSUs will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as he continues serving on the board through that date. Each RSU converts into one share of common stock upon settlement, bringing his direct holdings to 54,122 shares after the grant.
FIELDS HEIDI reported acquisition or exercise transactions in this Form 4 filing.
Phathom Pharmaceuticals director Heidi Fields received a grant of 24,122 Restricted Stock Units (RSUs) on May 19, 2026 under the company’s Non-Employee Director Compensation Program. All RSUs vest in full on the earlier of the first anniversary of grant or the next annual stockholder meeting, contingent on continued board service. Following this award, Fields holds 54,122 shares of common stock, reflecting routine equity compensation with no cash purchase involved.
Phathom Pharmaceuticals director Michael F. Cola received 24,122 Restricted Stock Units (RSUs) as an equity award. The grant was made under the company’s Non-Employee Director Compensation Program and is a compensation-related acquisition, not an open-market stock purchase.
The RSUs will vest 100% on the earlier of the first anniversary of the May 19, 2026 grant date or the next annual stockholder meeting, as long as Cola continues serving on the board through that date. Each RSU converts into one share of common stock, bringing his reported direct holdings to 63,920 shares after the grant.
Phathom Pharmaceuticals director Frank Karbe received an equity grant. On May 19, 2026, he was awarded 24,122 Restricted Stock Units under the company’s Non-Employee Director Compensation Program at no cash cost. Following this grant, he holds 91,622 shares of common stock directly. The RSUs vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, conditioned on his continued Board service. Each RSU converts into one share of common stock when it vests.
Phathom Pharmaceuticals director Theodore R. Schroeder received an equity award of 24,122 shares in the form of Restricted Stock Units (RSUs). These RSUs were granted under the company’s Non-Employee Director Compensation Program at no cash cost to him, increasing his direct holdings to 45,122 shares.
The award vests 100% on the earlier of the first anniversary of the May 19, 2026 grant date or the next annual stockholder meeting, as long as he continues serving on the board. Each RSU will convert into one share of common stock upon vesting, aligning his compensation with shareholder outcomes rather than representing an open-market purchase.
Phathom Pharmaceuticals director Asit Parikh reported gifting 80,000 shares of Common Stock. On March 10, 2026, he made two bona fide gift transfers of 40,000 shares each, with no cash consideration.
After these gifts, Parikh directly holds 10,500 shares and indirectly holds 120,500 shares through a trust for the benefit of his spouse, for which he serves as trustee. These are non-market, charitable-style transfers rather than open-market sales.
Phathom Pharmaceuticals Principal Accounting Officer Robert Charles Breedlove reported stock-based compensation activity in common stock. He received 13,000 restricted stock units and 2,790 performance stock units on February 27, 2026. The performance units relate to a grant from February 27, 2025 with performance criteria confirmed on February 27, 2026. To cover tax withholding on these awards, 964 shares tied to performance stock units and 414 shares tied to RSUs were surrendered back to the company at $12.56 per share. After these transactions, he directly holds 61,480 common shares and indirectly holds 6,945.4 shares through a 401(k) account.
Phathom Pharmaceuticals’ chief legal officer and corporate secretary Anne Marie Cook reported equity compensation activity in company common stock. On February 10, 2026, she acquired 3,461 shares at $0 upon vesting of performance stock units granted on June 23, 2025 after performance criteria were met.
On the same date, 1,535 shares were disposed of at $12.82 to satisfy the issuer’s tax withholding obligation related to that vesting. After these transactions, Cook directly owned 88,660 shares, which include 1,722 shares previously acquired through the company’s employee stock purchase plan in January 2026.
Phathom Pharmaceuticals President and CEO Steven L. Basta reported equity compensation activity in company stock. On February 10, 2026, he acquired 12,362 shares of common stock at $0 per share from the vesting of performance stock units granted on April 3, 2025, after performance criteria were met. On the same day, 6,277 shares were disposed of at $12.82 per share, surrendered to Phathom to satisfy tax withholding obligations related to the award. Following these transactions, he directly owned 373,315 shares of common stock, which includes 2,410 shares previously acquired under the employee stock purchase plan in January 2026.
Phathom Pharmaceuticals director Asit Parikh reported an internal share transfer involving 80,500 shares of common stock on January 23, 2026. The filing shows these shares moved for no consideration from his direct holdings to a trust for the benefit of his spouse, where he serves as trustee.
After the transactions, Parikh directly holds 50,500 shares and indirectly holds 80,500 shares through the trust. The transferred shares are subject to a lock-up agreement linked to an underwriting agreement dated January 7, 2026, and the trust has agreed to be bound by the same lock-up terms.
Phathom Pharmaceuticals, Inc. insider updates share holdings. Principal Accounting Officer Robert Charles Breedlove reported the surrender of 776 shares of common stock on 01/21/2026 at a price of $13.61 per share. According to the footnote, these shares represent stock underlying restricted stock units that were surrendered to Phathom to cover tax withholding obligations, rather than an open-market sale. After this transaction, Breedlove beneficially owned 47,068 shares of Phathom common stock directly and 6,945.4 shares indirectly through a 401(k) plan.
Phathom Pharmaceuticals director Asit Parikh exercised stock options to acquire 8,750 shares of common stock. On 01/13/2026, he converted 8,750 derivative securities labeled as Common Stock (Right to Buy) at an exercise price of $10.30 per share into 8,750 shares of Phathom common stock in a transaction coded "M" (option exercise).
Following this transaction, Parikh directly beneficially owned 131,000 shares of Phathom Pharmaceuticals common stock. The filing does not show any sale of shares in connection with this option exercise; it simply reflects the option conversion and updated direct ownership.
Phathom Pharmaceuticals, Inc. reported an equity award transaction for its President, CEO and Director, Steven L. Basta. On January 2, 2026, he received 251,034 restricted stock units (RSUs) of common stock at a price of $0 per share, increasing his directly held common stock to 364,820 shares after the transaction. Each RSU represents a right to receive one share of common stock.
The RSUs vest over three years, with one-third of the award vesting on each of the first three anniversaries of January 2, 2026, subject to his continued service. On the same date, he was also granted a stock option to purchase 226,156 shares of common stock at an exercise price of $15.71 per share, expiring on January 1, 2036. One forty-eighth of the option vests monthly following the vesting commencement date, conditioned on his continuous service.
Phathom Pharmaceuticals, Inc. President and CEO Steven L. Basta exercised 90,000 performance stock units, receiving an equal number of common shares on November 28, 2025. In connection with this vesting, 48,375 shares were delivered to the issuer at $15.62 per share to satisfy tax withholding obligations. After these transactions, he held 83,250 shares of common stock directly. A grant on April 3, 2025 covered 360,000 performance stock units, of which 90,000 vested on September 25, 2025 and another 90,000 on November 28, 2025; remaining units vest upon achievement of stock price hurdles over four years.
Phathom Pharmaceuticals (PHAT) insider filing: The company’s Principal Accounting Officer reported a sale of common stock on 11/03/2025. The filing shows 524 shares sold at $13.51 (transaction code S).
The footnote states the shares were sold to satisfy tax withholding obligations upon the settlement of restricted stock units. Following the transaction, beneficial ownership stands at 47,407 shares held directly and 6,945.4 shares held indirectly via a 401(k).
Sanjeev Narula, Chief Financial & Business Officer of Phathom Pharmaceuticals, Inc. (PHAT), reported a grant of 144,000 restricted stock units (RSUs) on 10/06/2025. Each RSU vests in three equal installments with 33.33% vesting on each of the first three anniversaries of the 10/06/2025 vesting commencement date, subject to continued service. The filing is an amendment submitted on 10/08/2025 to correct an omission in the Form 4 originally filed on 10/07/2025. Each RSU represents a contingent right to one share of common stock, and the report shows 144,000 shares beneficially owned following the grant.
Phathom Pharmaceuticals, Inc. (PHAT) reported a Section 16 officer equity award for Chief Financial & Business Officer Sanjeev Narula. On 10/06/2025 Mr. Narula was granted a stock option to buy 200,000 shares of common stock at an exercise price of $11.61 per share. The option is exercisable through 10/05/2036.
The award vests 25% on 10/06/2026 with the remainder vesting in equal monthly installments over the following three years, subject to continued service. The Form 4 was signed on 10/07/2025.
Steven L. Basta, President and CEO and a director of Phathom Pharmaceuticals, Inc. (PHAT), reported stock and derivative transactions on Form 4. On 09/25/2025 he acquired 90,000 shares of common stock upon vesting of performance stock units granted 04/03/2025; those 90,000 shares were reported as acquired at $0 and increased his direct beneficial ownership to 90,000 shares. The filing also shows the surrender of 48,375 shares to the issuer to cover tax withholding at a price of $11.66 per share, leaving 41,625 shares after that disposition. The reporting person holds 270,000 shares underlying performance stock units after the reported vesting event, reflecting a grant of 360,000 PSUs on 04/03/2025 of which 90,000 vested due to achievement of a stock-price hurdle. The remaining PSUs vest upon future stock-price hurdles through four years from the grant, subject to continued service.